Back  |
-
Subscribe to newsletter
 News
-
Get listed our directory
Pharmaceutical Research Centers
Jordan's Associations
Dental Laboratories
Nursing Centers
Medical Centers
Fitness Centers
Beauty Centers
Optic Centers
Drugstores
Hospitals
Doctors
Dentists
Dietitian
Companies
Pharmacies
Dental Centers
Herbal Centers
Scientific Offices
Infertility Centers
Dead Sea Factories
Medical Laboratories
Pharmaceutical Factories
Drug for Severe Adult Sepsis: The FDA has approved drotrecogin alfa (activated)...

The FDA has approved drotrecogin alfa (activated) (Xigris, Eli Lilly, Indianapolis), a recombinant form of human activated protein C, for the reduction of mortality in adults with severe sepsis (associated with acute organ dysfunction).

The effectiveness of the drug was shown in a multicenter, randomized, double-blind, placebo-controlled trial of 1690 adult patients with severe sepsis. Entry criteria included a systemic inflammatory response presumed due to infection and at least one of the following: cardiovascular, respiratory, or renal dysfunction; thrombocytopenia; or metabolic acidosis.

Patients received a 96-hour infusion of Xigris at 24 µg/kg per hour (the recommended dosage) or placebo within 48 hours after onset of the first sepsis-induced organ dysfunction. The primary efficacy end point was all-cause mortality assessed 28 days after the start of Xigris administration. The study was terminated after a planned interim analysis because of significantly lower mortality in patients who received Xigris (210 [25%] of 850) vs placebo (259 [31%] of 840). The observed reduction in mortality was limited to severe sepsis patients who had a higher risk of death based on acute physiology and chronic health status at study entry.

Bleeding is the most common serious adverse effect associated with Xigris therapy, and the drug is contraindicated in patients with conditions in which bleeding presents high risk of death or significant morbidity. Patients taking Xigris may develop serious bleeding, including intracranial hemorrhage (approximately 1%). During the 28-day study period, 25% of the Xigris-treated vs 18% of the placebo-treated patients experienced at least one bleeding event, in most cases ecchymoses or gastrointestinal tract bleeding.

Xigris is not indicated for all patients with severe sepsis, but only for those with relatively high risk of death. Safety and effectiveness of the drug have not been established in children.
 

Published on 11 January 2002
 
 
  Are You interested to promote your self @ Yemen, Bahrain, Sudan, Libya & Arbeel?
  Severe stress in pregnancy may affect fetal growth
  Weight loss may cut risk of colorectal growths
  Flu shot does not cut risk of death in elderly
  Low Levels of Brain Chemical May Control Appetite
  Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose
  Wearing an underwire bra increases your risk of getting breast cancer
  Businesswomen from Uganda and Ghana were second and third as Jordanian entrepreneur takes first prize at UNCTAD’s debut women in business awards
  Jordanian Woman Wins First Prize: Sana Burgan
  "Concept, Indication and Handling of the Friadent Implant System Xive" courses will be held in Jordan Soon

  Dr. Joudeh Operated on a big Tumor.....

  HealLand Newspaper
  HealLand Jordan Directory
  Happy Eid
  Are You Targeting Jordan, Yemen, Bahrain and All the Arabic World
  Afurnished Clinic 4 Rent..

  Med Grant Est. launched it's 2nd edition of HealLand Jordan book.

  On the occasion of The New Year, Johealth seize this......
  Watch Us Today 8th of Sep. On Jordan TV @ 5:40
  HealLand Jordan 2nd Edition
  During menopause, estrogen levels go down. At the same time, bone breakdown (resorption) may increase.
  A Star Sent From Heaven to Dr. Samer Sunna - A Girl

  Dr. Sana Hammouri the First and Only Jordanian Female General Surgeon in the private sector

  Dr. Disi, One of the pioneer Orthopeadics doctors in Jordan

  Sabarini Consultation & Training Est. Offers a lot of services

  For Sale.... Siemens Sonoline SX Sector Ultrasound Scanning Machine

  NEW YORK (Reuters Health) - Older people who exercise are less likely to be depressed,
  LabTechONE is now a client of mayo Medical Laboratories and will provide comprehensive laboratory services
  Chicco, the Italian firm as we all know, is one of the most famous brands world wide....
  JOHEALTH has moved !

  Rheumatoid Arthritis Treatment: The FDA has approved anakinra as adjunctive therapy for..
  FDA APPROVES NEW WEARABLE DEFIBRILLATOR
FOR SERIOUSLY ILL HEART PATIENTS.....
  Breast Tissue Ablation Device: The FDA has approved Cryocare Surgical System....
  Drug for Severe Adult Sepsis: The FDA has approved drotrecogin alfa (activated)...
  On the occasion of Ramadan, Johealth seize this......

  Dr. Najib Layyous, One of the most pioner doctors in Jordan specialized in Infertility...
  Under the unprecedented support of his Royal Majesty King Abdullah II, to further promote the use of internet services for the benefit of the Jordanian people
  A Jordanian Pediatrician invents the first Natural Anti Diarrhea Medication for babies, children and adults.
  FDA issues nationwide alert on the recall of "PIERRE FABRE physicians formula eye makeup remover lotion" because of health risk.
  FDA Approves First Pacemaker For Congestive Heart Failure
  FDA updates safety information for MICONAZOLE VAGINAL cream and suppositories
Copyright © 2000-2018 JoHealth. All rights reserved
info@johealth.com

Powered by Softimpact